Last edition
News about "Stempeutics gets DCGI nod for phase-III clinical t"
Stempeutics gets DCGI nod for phase-III clinical trial on its product for treating COVID patients
Stempeutics yesterday said it has received DCGI clearance to conduct phase-III clinical trial on its product for treating COVID-19 patients suffering from Acute Respiratory Distress Syndrome (ARDS). The company will be using its stem cell product, Stempeucel, for conducting the label extension phase-III clinical trial
Stempeutics Gets DCGI Nod For Phase-III Clinical T | 20/01/2022 | By Darshana | 500
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy